PubMed:24281730 / 572-883
Annnotations
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T6 | 0-311 | Sentence | denotes | We conducted a 32-week, double-blind, placebo-controlled, cross-over and randomized trial that implicated two arms: arm A, 20 patients received levocetirizine, montelukast with or without levocetirizine or placebo; arm B, 20 patients received desloratadine, montelukast with or without desloratadine or placebo. |
T6 | 0-311 | Sentence | denotes | We conducted a 32-week, double-blind, placebo-controlled, cross-over and randomized trial that implicated two arms: arm A, 20 patients received levocetirizine, montelukast with or without levocetirizine or placebo; arm B, 20 patients received desloratadine, montelukast with or without desloratadine or placebo. |
luoyt2021_800_3
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T6 | 258-269 | CI | denotes | montelukast |
T7 | 160-171 | CI | denotes | montelukast |
T25 | 144-158 | CI | denotes | levocetirizine |
T27 | 188-202 | CI | denotes | levocetirizine |
T28 | 243-256 | CI | denotes | desloratadine |
T29 | 286-299 | CI | denotes | desloratadine |
Linmchun_800_3
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 144-158 | CI | denotes | levocetirizine |
T5 | 160-171 | CI | denotes | montelukast |
T6 | 188-202 | CI | denotes | levocetirizine |
T7 | 206-213 | CI | denotes | placebo |
T8 | 243-256 | CI | denotes | desloratadine |
T9 | 258-269 | CI | denotes | montelukast |
T10 | 286-299 | CI | denotes | desloratadine |
T11 | 303-310 | CI | denotes | placebo |